Literature DB >> 7898937

Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth.

E K Han1, A Sgambato, W Jiang, Y J Zhang, R M Santella, Y Doki, A M Cacace, I Schieren, I B Weinstein.   

Abstract

Amplification and/or increased expression of cyclin D1 occurs in an appreciable fraction of primary human breast carcinomas and several other types of human cancer. In addition, overexpression of cyclin D1 in rodent fibroblasts enhances growth and malignant transformation. The present study demonstrates that the extent of amplification and expression of cyclin D1 varies widely amongst a series of cell lines established from normal human mammary epithelium or human breast carcinomas. The HBL-100 mammary epithelial cell line did not display amplification or increased expression of cyclin D1. We used retrovirus-mediated transduction to obtain derivatives of this cell line that stably expressed relatively high levels of an exogenous cyclin D1 cDNA. These derivatives displayed an increased doubling time, decreased saturation density, decreased cloning efficiency, decreased anchorage-independent growth, an increased fraction of cells in the S-phase, and decreased tumorigenicity. Thus, increased expression of cyclin D1 in this cell line markedly inhibits rather than enhances growth, which may be due to the prolongation of S-phase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7898937

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Lactation defect in mice lacking the helix-loop-helix inhibitor Id2.

Authors:  S Mori; S I Nishikawa; Y Yokota
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

2.  HES-1 repression of differentiation and proliferation in PC12 cells: role for the helix 3-helix 4 domain in transcription repression.

Authors:  P Castella; S Sawai; K Nakao; J A Wagner; M Caudy
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

3.  Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.

Authors:  G Wani; I Noyes; G E Milo; S M D'Ambrosio
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

4.  Role of cyclins in neuronal differentiation of immortalized hippocampal cells.

Authors:  W Xiong; R Pestell; M R Rosner
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

5.  Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells.

Authors:  M Meyyappan; H Wong; C Hull; K T Riabowol
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

6.  Repression of cyclin D1 expression does not contribute to initiation or maintenance of cell transformation by adenovirus type 5 E1.

Authors:  O Kranenburg; P Keblusek; A J Van der Eb; A Zantema
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

7.  Environmental chemical carcinogens induce transformation of breast epithelial cells from women with familial history of breast cancer.

Authors:  Y F Hu; I H Russo; U Zalipsky; H T Lynch; J Russo
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997 Jul-Aug       Impact factor: 2.416

8.  Functional consequences of cyclin D1 overexpression in human mammary luminal epithelial cells.

Authors:  T Kamalati; D Davies; J Titley; M R Crompton
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

9.  Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer.

Authors:  J S de Jong; P J van Diest; R J Michalides; P van der Valk; C J Meijer; J P Baak
Journal:  Mol Pathol       Date:  1998-02

10.  Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells.

Authors:  Archana Thakur; Yuan Sun; Aliccia Bollig; Jack Wu; Hector Biliran; Sanjeev Banerjee; Fazlul H Sarkar; D Joshua Liao
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.